These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 26943851)

  • 21. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
    Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
    Wick A; Kessler T; Platten M; Meisner C; Bamberg M; Herrlinger U; Felsberg J; Weyerbrock A; Papsdorf K; Steinbach JP; Sabel M; Vesper J; Debus J; Meixensberger J; Ketter R; Hertler C; Mayer-Steinacker R; Weisang S; Bölting H; Reuss D; Reifenberger G; Sahm F; von Deimling A; Weller M; Wick W
    Neuro Oncol; 2020 Aug; 22(8):1162-1172. PubMed ID: 32064499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
    Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
    J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
    Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
    J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
    Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
    Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment options and outcomes for glioblastoma in the elderly patient.
    Arvold ND; Reardon DA
    Clin Interv Aging; 2014; 9():357-67. PubMed ID: 24591820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
    Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
    Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
    Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
    Harris G; Jayamanne D; Wheeler H; Gzell C; Kastelan M; Schembri G; Brazier D; Cook R; Parkinson J; Khasraw M; Louw S; Back M
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):802-810. PubMed ID: 28602411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients.
    Yin AA; Cai S; Dong Y; Zhang LH; Liu BL; Cheng JX; Zhang X
    J Neurooncol; 2014 Jan; 116(2):315-24. PubMed ID: 24178440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
    Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
    Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
    Omuro A; Brandes AA; Carpentier AF; Idbaih A; Reardon DA; Cloughesy T; Sumrall A; Baehring J; van den Bent M; Bähr O; Lombardi G; Mulholland P; Tabatabai G; Lassen U; Sepulveda JM; Khasraw M; Vauleon E; Muragaki Y; Di Giacomo AM; Butowski N; Roth P; Qian X; Fu AZ; Liu Y; Potter V; Chalamandaris AG; Tatsuoka K; Lim M; Weller M
    Neuro Oncol; 2023 Jan; 25(1):123-134. PubMed ID: 35419607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients.
    Hegi ME; Oppong FB; Perry JR; Wick W; Henriksson R; Laperriere NJ; Gorlia T; Malmström A; Weller M
    Neuro Oncol; 2024 Oct; 26(10):1867-1875. PubMed ID: 38912869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
    Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE
    J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
    Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
    J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MGMT gene promoter methylation in pediatric glioblastomas.
    Srivastava A; Jain A; Jha P; Suri V; Sharma MC; Mallick S; Puri T; Gupta DK; Gupta A; Sarkar C
    Childs Nerv Syst; 2010 Nov; 26(11):1613-8. PubMed ID: 20585787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.